Japan approves world's first iPS cell treatments for heart disease and Parkinson's

nippon.com

Japan has conditionally approved the world's first iPS cell-derived regenerative therapies for heart disease and Parkinson's. The treatments, ReHeart and Amchepry, developed by Cuorips and Sumitomo Pharma respectively, will be covered by public health insurance. Full approval requires further clinical data collection over seven years, with specific patient targets for each therapy.


With a significance score of 5.8, this news ranks in the top 0.5% of today's 30863 analyzed articles.

Get summaries of news with significance over 5.5 (usually ~10 stories per week). Read by 10,000+ subscribers: